ADMINISTRATION SYSTEMIQUE DE VECTEURS DE VIRUS CODANT POUR L'UROCORTINE-2 ET GENES ASSOCIES POUR TRAITER UN DYSFONCTIONNEMENT CARDIAQUE LIE AU DIABETE ET UNE INSUFFISANCE CARDIAQUE CONGESTIVE
In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (CHF) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (AAV), e.g., an AAV8 serotype； and administering to an individual or a patient in need thereof, such as a type 2 diabetic (T2DM), e.g., by IV administration, thereby treating, ameliorating or protecting against (preventing) the T2DM and/or the diabetes-related cardiac dysfunction in the individual or patient.
